IceCure Medical (NASDAQ:ICCM – Get Free Report) and Nanovibronix (NASDAQ:FEED – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.
Volatility and Risk
IceCure Medical has a beta of 0.45, meaning that its share price is 55% less volatile than the S&P 500. Comparatively, Nanovibronix has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for IceCure Medical and Nanovibronix, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| IceCure Medical | 2 | 0 | 3 | 0 | 2.20 |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
Earnings and Valuation
This table compares IceCure Medical and Nanovibronix”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| IceCure Medical | $3.38 million | 1.76 | -$15.06 million | ($8.52) | -0.20 |
| Nanovibronix | $1.93 million | 0.19 | -$18.18 million | ($117.28) | -0.00 |
IceCure Medical has higher revenue and earnings than Nanovibronix. IceCure Medical is trading at a lower price-to-earnings ratio than Nanovibronix, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares IceCure Medical and Nanovibronix’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| IceCure Medical | -427.67% | -174.26% | -112.58% |
| Nanovibronix | -1,093.61% | -60.73% | -48.48% |
Insider & Institutional Ownership
0.6% of IceCure Medical shares are held by institutional investors. Comparatively, 16.4% of Nanovibronix shares are held by institutional investors. 2.4% of IceCure Medical shares are held by company insiders. Comparatively, 12.2% of Nanovibronix shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Summary
IceCure Medical beats Nanovibronix on 8 of the 14 factors compared between the two stocks.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
About Nanovibronix
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for IceCure Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IceCure Medical and related companies with MarketBeat.com's FREE daily email newsletter.
